West Pharmaceutical
213 hedge funds and large institutions have $4.05B invested in West Pharmaceutical in 2015 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 90 increasing their positions, 75 reducing their positions, and 23 closing their positions.
526% more call options, than puts
Call options by funds: $789K | Put options by funds: $126K
20% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 75
16% more capital invested
Capital invested by funds: $3.5B → $4.05B (+$549M)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
1.06% more ownership
Funds ownership: 92.56% → 93.62% (+1.1%)
5% less funds holding
Funds holding: 225 → 213 (-12)
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$171M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$24.6M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$13.2M |
| 4 |
HIM
Hermes Investment Management
London Uk,
United Kingdom
|
+$10.1M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
+$6.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$19.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.5M |
| 3 |
DIA
Denver Investment Advisors
Denver,
Colorado
|
-$17M |
| 4 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$16.4M |
| 5 |
MACM
March Altus Capital Management
Greenwich,
Connecticut
|
-$11.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
Two Sigma Advisers
New York
| – | -$407K | -7,638 | Closed |
|
|
CCM
227
Coldstream Capital Management
Bellevue,
Washington
| – | -$253K | -4,755 | Closed |
|
|
LI
228
LMCG Investments
Boston,
Massachusetts
| – | -$217K | -4,083 | Closed |
|
|
TI
229
Trexquant Investment
Stamford,
Connecticut
| – | -$214K | -4,027 | Closed |
|
230
Tudor Investment Corp
Stamford,
Connecticut
| – | -$202K | -3,800 | Closed |
|
|
OSAM
231
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | -$127K | -2,385 | Closed |
|
|
CG
232
Colony Group
Boston,
Massachusetts
| – | -$58K | -1,080 | Closed |
|
|
MA
233
MUFG Americas
New York
| – | -$12K | -220 | Closed |
|
|
BRWA
234
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$9 | -177 | Closed |
|
|
BC
235
Bartlett & Co
Cincinnati,
Ohio
| – | -$9K | -169 | Closed |
|
236
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$6K | -105 | Closed |
|
WST Hedge Fund Activity: Q1 2015 in Review
213 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q1 2015, worth a combined $4.05B — up 16% from $3.5B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of WST and 14 opened new positions — a net loss of 9 holders — while 75 trimmed existing stakes and 90 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $171M. The largest seller was State Street, cutting an estimated $19.1M.
- 213 institutional investors held West Pharmaceutical (WST) as of Q1 2015, down from 225 in Q4 2014.
- Funds reported $4.05B of West Pharmaceutical stock for Q1 2015, up 16% quarter-over-quarter.
- 14 funds opened new West Pharmaceutical positions in Q1 2015 and 23 closed out, a net change of -9 holders.
- The largest West Pharmaceutical buyer in Q1 2015 was T. Rowe Price Associates, an estimated $171M added.
- The largest West Pharmaceutical seller in Q1 2015 was State Street, an estimated $19.1M sold.
Based on aggregated 13F filings for Q1 2015.